Showing results (31-40 of 102) with videos related to
Sort By:
Pageof 11
General Hospital Psychiatry|April 21, 2026
Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic reviewGabrielle F M Lovell, Shreya Vasudeva, Diana K Orsini, et al.Clinical Pharmacology and Therapeutics|May 28, 2026
The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of DepressionGia Han Le, Sabrina Wong, Danica E Johnson, et al.Journal of Affective Disorders|December 5, 2024
Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trialsShakila Meshkat, Angela T H Kwan, Gia Han Le, et al.CNS Spectrums|August 12, 2025
Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatmentsGia Han Le, Sabrina Wong, Stavroula Bargiota, et al.CNS Spectrums|November 20, 2024
Ketamine for the Treatment of Psychiatric Disorders: A Systematic Review and Meta-AnalysisAngela T H Kwan, Moiz Lakhani, Gurkaran Singh, et al.CNS Spectrums|June 2, 2025
A systematic review of anti-suicidal effects of sedative-hypnotics and cognitive behavioral therapy for insomniaKyle Valentino, Kayla Teopiz, Sabrina Wong, et al.CNS Spectrums|December 27, 2024
Anatomical, behavioral, and cognitive teratogenicity associated with valproic acid: a systematic reviewKyle Valentino, Kayla M Teopiz, Angela T H Kwan, et al.Journal of Affective Disorders|July 19, 2024
A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse existsAngela T H Kwan, Joshua D Rosenblat, Rodrigo B Mansur, et al.Journal of Neuroimmunology|April 2, 2025
Peripheral and central inflammation in depression: How large is the gap and can we bridge it with PET neuroimaging and neural-derived extracellular vesicles?Cristian-Daniel Llach, Gia Han Le, Hiya Shah, et al.Expert Opinion on Drug Safety|May 28, 2024
Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS)Roger S McIntyre, Sabrina Wong, Angela T H Kwan, et al.Pageof 11